Davis Polk advised Credit Suisse Securities (USA) LLC and Cowen and Company, LLC as joint book-running managers in connection with the $70.5 million initial public offering of common stock by BIND Therapeutics, Inc. BIND’s common stock is listed on the Nasdaq Global Select Market under the symbol "BIND."

Based in Cambridge, Massachusetts, BIND Therapeutics is a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurin.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Daniel J. Luskin and Jeffrey T. Hedrick. The tax team included partner Rachel D. Kleinberg and associate Catherine Paskoff Chang. The intellectual property team included associates Bruce Rose-Innes and Nicholas D. DiChiara. Counsel Cynthia Akard and Marcie A. Goldstein provided executive compensation and FINRA advice, respectively. Members of the Davis Polk team are based in the Menlo Park and New York offices.